伊立替康联合顺铂治疗复发卵巢癌40例的临床疗效

目的:观察伊立替康联合顺铂治疗复发卵巢癌的效果。方法:将82例复发卵巢癌病人分成2组,试验组(40例)和对照组(42例),试验组每个疗程给予伊立替康200mg,在化学治疗(化疗)的d1,8静脉滴注(静滴);顺铂100mg,d1～5静滴;对照组氟尿嘧啶1500mg和顺铂100mg,按常规剂量给予。观察2组卵巢癌上皮抗原(CA125)值、病灶缩小情况、生存率、不同病理类型对其敏感度以及不良反应的差异。结果:试验组CA125下降率22%,病灶缩小率28%,1年生存率70%,对照组分别为10%,7%,33%,差异有显著意义(P<0.05)。透明细胞癌较浆液性癌对伊立替康更敏感。试验组的不良反应主要是腹泻、呕吐、中性粒细胞减少和肠梗阻。结论:伊立替康联合顺铂可成为一种有效的、优于对照组的治疗复发卵巢癌的药物。

Clinical effect of irinotecan combined with cisplatin for treating recurring ovarian cancer in 40 patients

AIM: To observe the therapeutic efficacy of recurrent ovarian cancer by ininotecan. METHODS: Eighty-two recurrent ovarian cancer patients were divided into two groups. The patients in trial group were given infusion of irinotecan 200 mg per period of treatment on the d 1 and d 8, and infusion of 20 mg cisplatin from d 1 to d 5. The patients in control group were administrated fluorouracil and cisplatin with routine doses.We compared the differences of cancer antagen 125(CA 125), tumor size ,one year survival rate, sensitive to themotherapy and advere reactions between two groups. RESULTS: The decreases of CA 125, tumor size, and the one year survival rate in trial group were 22 %, 28 % and 70 % compared with control group of 10 %, 7 %, and 33 %, respectively. Ovarian serous tumors showed more sensitive response than clear cell tumors. Adverse reactions in trial group were diarrhea, emesis, neutropenia and ileus. CONCLUSION: Irinotecan combined with cisplatin are more superior than other drugs for the treatment of recurrent ovarian cancer.